TARCEVA for Lung neoplasm malignant: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 316 adverse event reports in the FDA FAERS database where TARCEVA was used for Lung neoplasm malignant.
Most Reported Side Effects for TARCEVA
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 274 | 44.0% | 274 | 12 |
| Rash | 81 | 13.0% | 24 | 18 |
| Diarrhoea | 65 | 10.4% | 20 | 24 |
| Incorrect dose administered | 48 | 7.7% | 29 | 4 |
| Nausea | 31 | 5.0% | 9 | 11 |
| Malignant neoplasm progression | 29 | 4.7% | 19 | 5 |
| Vomiting | 25 | 4.0% | 4 | 13 |
| Disease progression | 21 | 3.4% | 9 | 3 |
| Off label use | 16 | 2.6% | 9 | 2 |
| Decreased appetite | 15 | 2.4% | 4 | 7 |
| Dehydration | 15 | 2.4% | 1 | 12 |
| Dry skin | 15 | 2.4% | 4 | 2 |
| Alopecia | 14 | 2.3% | 1 | 1 |
| Fatigue | 13 | 2.1% | 2 | 5 |
| Dyspnoea | 12 | 1.9% | 2 | 8 |
Other Indications for TARCEVA
Product used for unknown indication (98)
Non-small cell lung cancer (64)
Lung carcinoma cell type unspecified stage 0 (24)
Lung adenocarcinoma (20)
Pancreatic carcinoma (19)
Bronchial carcinoma (15)
Neoplasm malignant (12)
Tracheal cancer (7)
Lung cancer metastatic (5)
Lung carcinoma cell type unspecified stage iv (5)
Other Drugs Used for Lung neoplasm malignant
ERLOTINIB (9,207)
OSIMERTINIB (4,754)
NIVOLUMAB (4,197)
PEMBROLIZUMAB (3,575)
CARBOPLATIN (3,487)
ALECTINIB (2,932)
PEMETREXED (2,422)
CRIZOTINIB (1,949)
BEVACIZUMAB (1,810)
PACLITAXEL (1,747)